Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus

NCT00927394 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00927394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00927394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2009
Completion date
October 31, 2011
Enrollment
1,143 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension